- Home
- FOXX vs CVKD Comparison
FOXX vs CVKD Comparison
Compare FOXX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- CVKD
- Stock Information
- Founded
- FOXX 2017
- CVKD 2022
- Country
- FOXX United States
- CVKD United States
- Employees
- FOXX N/A
- CVKD N/A
- Industry
- FOXX
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- FOXX
- CVKD Health Care
- Exchange
- FOXX Nasdaq
- CVKD Nasdaq
- Market Cap
- FOXX 33.5M
- CVKD 31.5M
- IPO Year
- FOXX N/A
- CVKD 2023
- Fundamental
- Price
- FOXX $5.32
- CVKD $16.96
- Analyst Decision
- FOXX
- CVKD Strong Buy
- Analyst Count
- FOXX 0
- CVKD 1
- Target Price
- FOXX N/A
- CVKD $32.00
- AVG Volume (30 Days)
- FOXX 13.4K
- CVKD 20.4K
- Earning Date
- FOXX 05-15-2025
- CVKD 05-08-2025
- Dividend Yield
- FOXX N/A
- CVKD N/A
- EPS Growth
- FOXX N/A
- CVKD N/A
- EPS
- FOXX N/A
- CVKD N/A
- Revenue
- FOXX $42,988,015.00
- CVKD N/A
- Revenue This Year
- FOXX N/A
- CVKD N/A
- Revenue Next Year
- FOXX N/A
- CVKD N/A
- P/E Ratio
- FOXX N/A
- CVKD N/A
- Revenue Growth
- FOXX 98.81
- CVKD N/A
- 52 Week Low
- FOXX $2.45
- CVKD $5.70
- 52 Week High
- FOXX $14.99
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- CVKD 51.31
- Support Level
- FOXX N/A
- CVKD $15.85
- Resistance Level
- FOXX N/A
- CVKD $17.00
- Average True Range (ATR)
- FOXX 0.00
- CVKD 1.34
- MACD
- FOXX 0.00
- CVKD 0.21
- Stochastic Oscillator
- FOXX 0.00
- CVKD 88.11
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.